156 related articles for article (PubMed ID: 21712473)
1. A dual-targeting anticancer approach: soil and seed principle.
Li J; Sun Z; Zhang J; Shao H; Cona MM; Wang H; Marysael T; Chen F; Prinsen K; Zhou L; Huang D; Nuyts J; Yu J; Meng B; Bormans G; Fang Z; de Witte P; Li Y; Verbruggen A; Wang X; Mortelmans L; Xu K; Marchal G; Ni Y
Radiology; 2011 Sep; 260(3):799-807. PubMed ID: 21712473
[TBL] [Abstract][Full Text] [Related]
2. Sequential systemic administrations of combretastatin A4 Phosphate and radioiodinated hypericin exert synergistic targeted theranostic effects with prolonged survival on SCID mice carrying bifocal tumor xenografts.
Li J; Cona MM; Chen F; Feng Y; Zhou L; Zhang G; Nuyts J; de Witte P; Zhang J; Yu J; Oyen R; Verbruggen A; Ni Y
Theranostics; 2013; 3(2):127-37. PubMed ID: 23423247
[TBL] [Abstract][Full Text] [Related]
3. Tumor necrosis targeted radiotherapy of non-small cell lung cancer using radioiodinated protohypericin in a mouse model.
Liu X; Jiang C; Zhang D; Gao M; Peng F; Huang D; Sun Z; Ni Y; Zhang J; Yin Z
Oncotarget; 2015 Sep; 6(28):26400-10. PubMed ID: 26305548
[TBL] [Abstract][Full Text] [Related]
4. Intra-individual comparison of therapeutic responses to vascular disrupting agent CA4P between rodent primary and secondary liver cancers.
Liu YW; De Keyzer F; Feng YB; Chen F; Song SL; Swinnen J; Bormans G; Oyen R; Huang G; Ni YC
World J Gastroenterol; 2018 Jul; 24(25):2710-2721. PubMed ID: 29991876
[TBL] [Abstract][Full Text] [Related]
5. Improved clearance of radioiodinated hypericin as a targeted anticancer agent by using a duodenal drainage catheter in rats.
Cona MM; Feng Y; Verbruggen A; Oyen R; Ni Y
Exp Biol Med (Maywood); 2013 Dec; 238(12):1437-49. PubMed ID: 24146264
[TBL] [Abstract][Full Text] [Related]
6. Diffusion-weighted MR imaging in monitoring the effect of a vascular targeting agent on rhabdomyosarcoma in rats.
Thoeny HC; De Keyzer F; Chen F; Ni Y; Landuyt W; Verbeken EK; Bosmans H; Marchal G; Hermans R
Radiology; 2005 Mar; 234(3):756-64. PubMed ID: 15734932
[TBL] [Abstract][Full Text] [Related]
7. Radioiodinated hypericin: its biodistribution, necrosis avidity and therapeutic efficacy are influenced by formulation.
Cona MM; Alpizar YA; Li J; Bauwens M; Feng Y; Sun Z; Zhang J; Chen F; Talavera K; de Witte P; Verbruggen A; Oyen R; Ni Y
Pharm Res; 2014 Feb; 31(2):278-90. PubMed ID: 23934256
[TBL] [Abstract][Full Text] [Related]
8. Improved therapeutic outcomes of thermal ablation on rat orthotopic liver allograft sarcoma models by radioiodinated hypericin induced necrosis targeted radiotherapy.
Gao L; Zhang J; Ma T; Yao N; Gao M; Shan X; Ni Y; Shao H; Xu K
Oncotarget; 2016 Aug; 7(32):51450-51461. PubMed ID: 27285983
[TBL] [Abstract][Full Text] [Related]
9. Treatment of rodent liver tumor with combretastatin a4 phosphate: noninvasive therapeutic evaluation using multiparametric magnetic resonance imaging in correlation with microangiography and histology.
Wang H; Sun X; Chen F; De Keyzer F; Yu J; Landuyt W; Vandecaveye V; Peeters R; Bosmans H; Hermans R; Marchal G; Ni Y
Invest Radiol; 2009 Jan; 44(1):44-53. PubMed ID: 19034028
[TBL] [Abstract][Full Text] [Related]
10. Necrosis targeted radiotherapy with iodine-131-labeled hypericin to improve anticancer efficacy of vascular disrupting treatment in rabbit VX2 tumor models.
Shao H; Zhang J; Sun Z; Chen F; Dai X; Li Y; Ni Y; Xu K
Oncotarget; 2015 Jun; 6(16):14247-59. PubMed ID: 26036625
[TBL] [Abstract][Full Text] [Related]
11. Comparison of two vascular-disrupting agents at a clinically relevant dose in rodent liver tumors with multiparametric magnetic resonance imaging biomarkers.
Wang H; Cona MM; Chen F; Yu J; Feng Y; Li J; Keyzer FD; Marchal G; Ni Y
Anticancer Drugs; 2012 Jan; 23(1):12-21. PubMed ID: 21857503
[TBL] [Abstract][Full Text] [Related]
12. Small Molecule Sequential Dual-Targeting Theragnostic Strategy (SMSDTTS): from Preclinical Experiments towards Possible Clinical Anticancer Applications.
Li J; Oyen R; Verbruggen A; Ni Y
J Cancer; 2013; 4(2):133-45. PubMed ID: 23412554
[TBL] [Abstract][Full Text] [Related]
13. Radiopharmaceutical evaluation of (131)I-protohypericin as a necrosis avid compound.
Liu X; Feng Y; Jiang C; Lou B; Li Y; Liu W; Yao N; Gao M; Ji Y; Wang Q; Huang D; Yin Z; Sun Z; Ni Y; Zhang J
J Drug Target; 2015 Jun; 23(5):417-26. PubMed ID: 25655506
[TBL] [Abstract][Full Text] [Related]
14. Comparative study of iodine-123-labeled hypericin and (99m)Tc-labeled hexakis [2-methoxy isobutyl isonitrile] in a rabbit model of myocardial infarction.
Cona MM; Feng Y; Li Y; Chen F; Vunckx K; Zhou L; Van Slambrouck K; Rezaei A; Gheysens O; Nuyts J; Verbruggen A; Oyen R; Ni Y
J Cardiovasc Pharmacol; 2013 Sep; 62(3):304-11. PubMed ID: 23714775
[TBL] [Abstract][Full Text] [Related]
15. Sodium cholate, a solubilizing agent for the necrosis avid radioiodinated hypericin in rabbits with acute myocardial infarction.
Cona MM; Feng Y; Zhang J; Li Y; Verbruggen A; Oyen R; Ni Y
Drug Deliv; 2015 May; 22(3):427-35. PubMed ID: 24417698
[TBL] [Abstract][Full Text] [Related]
16. Exploring theranostic potentials of radioiodinated hypericin in rodent necrosis models.
Li J; Cona MM; Chen F; Feng Y; Zhou L; Yu J; Nuyts J; de Witte P; Zhang J; Himmelreich U; Verbruggen A; Ni Y
Theranostics; 2012; 2(10):1010-9. PubMed ID: 23139728
[TBL] [Abstract][Full Text] [Related]
17. Biodistribution and anti-tumor efficacy of intratumorally injected necrosis-avid theranostic agent radioiodinated hypericin in rodent tumor models.
Liu W; Zhang D; Feng Y; Li Y; Huang D; Jiang C; Gao M; Peng F; Wang X; Jing S; Jiang X; Ni Y; Zhang J
J Drug Target; 2015 May; 23(4):371-9. PubMed ID: 25572455
[TBL] [Abstract][Full Text] [Related]
18. Biodistribution and radiation dosimetry of radioiodinated hypericin as a cancer therapeutic.
Cona MM; Koole M; Feng Y; Liu Y; Verbruggen A; Oyen R; Ni Y
Int J Oncol; 2014 Mar; 44(3):819-29. PubMed ID: 24366374
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of hypericin: effect of aggregation on targeting biodistribution.
Liu X; Jiang C; Li Y; Liu W; Yao N; Gao M; Ji Y; Huang D; Yin Z; Sun Z; Ni Y; Zhang J
J Pharm Sci; 2015 Jan; 104(1):215-22. PubMed ID: 25395358
[TBL] [Abstract][Full Text] [Related]
20. Targetability and biodistribution of radioiodinated hypericin: comparison between microdosing and carrier-added preparations.
Cona MM; Li J; Feng Y; Chen F; Verbruggen A; Witte Pd; Oyen R; Ni Y
Anticancer Agents Med Chem; 2014; 14(6):852-61. PubMed ID: 24102315
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
